Metrics as of 10/13/2026, 06:53 PM (Berlin time), refresh in progress.
Evommune Stock
Evommune, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Luis C. Pena
- Employees
- 48
- Market cap
- $188 M
- IPO
- 06/11/2025
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic…
Evommune stock: price history
1D
-12.8%
1W
-17.3%
1M
-44.8%
6M
-81.2%
YTD
-69.8%
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
No date known
Volatility around earnings
~19% weaker price swings than usual
Ask the agents about Evommune
Analyst assessment of Evommune
PRICE TARGET LOW
US$8.00
CONSENSUS
US$25.00
MEDIAN
US$22.00
PRICE TARGET HIGH
US$50.00
0
STRONG BUY
3
BUY
2
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 09/09/2026
Evommune stock metrics
P/E
-1.83
P/B
0.67
EV/EBITDA
-1.74
RETURN ON EQUITY
-11.6%
NET MARGIN
0.0%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
52.9%
FLOAT SHARES
19,206,149
AVG. DAILY VOLUME (30D)
933,459
Insider transactions (SEC)
Pena Luis C.
Carver Kyle
KIRSCH ARTHUR S
Drew Janice Suzann
Drew Janice Suzann
Institutional holders
Comparable stocks
Frequently asked questions about Evommune stock
What does Evommune do?
Evommune, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Luis C. Pena, the company employs around 48 people.
The IPO was on 06/11/2025; the stock trades on NYSE under the ticker EVMN.
What do analysts say about Evommune stock?
5 analysts rate the stock, the consensus is Buy (as of 09/09/2026).
The average price target is US$25.00, ranging from US$8.00 to US$50.00, with a median of US$22.00.
This is an external assessment, not a statement by Market Jury.
When does Evommune report next?
Around past earnings, price swings were roughly -19% stronger than usual.
Does Evommune pay a dividend?
No, Evommune currently does not pay a dividend.
Which stocks are comparable to Evommune?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Evommune stock analyzed?
Clicking "Analyze stock" lets five strategies assess Evommune against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.